[ad_1]
Topline
Pfizer CEO Albert Bourla said Tuesday the company will be able to provide the U.S. 10% more vaccine doses than it originally agreed to by the end of May, a move that will boost vaccine supply after regulators recommended a pause on administering Johnson & Johnson’s vaccine.
Physician Assistant-Certified (PA-C) Alyssa Hernandez with the Stacy Medical Center administers a … [+]
Key Facts
In addition to ramping up production in May, Bourla said in a tweet the company can deliver a total of 300 million doses two weeks earlier than anticipated before the end of July.
The announcement comes after the CDC and FDA recommended a temporary halt to Johnson & Johnson’s vaccine over extremely rare blood clots from the shot—through the Biden administration has said the pause won’t significantly impact its overall vaccine plan because the Johnson & Johnson vaccine only makes up less than 5% of the recorded shots in the U.S. to date.
This is a developing story.
[ad_2]